Regulatory snapshots for biopharma and med tech in Asia-Pacific, including global submissions and approvals, and other regulatory decisions and designations: Airs Medical, Daiichi Sankyo, Immutep, Leo, Mabwell, Merck, Reach Surgical.
Biopharma and med-tech happenings in Asia-Pacific, including deals and partnerships, and other news in brief: 4D Path, Aligos, Amgen, Amoytop, Astellas, Daiichi Sankyo, Interna, Kazia, Mabwell, Sanofi, Vectus Biosystems, Vir, Wayfinder, Xortx.
Clinical updates for biopharma and med tech in Asia-Pacific, including data readouts and publications: Acerand, Biontech, Caliway, Duality, Kelun-Biotech, Samsung Biologics.
Oricell Therapeutics Holdings Ltd closed a $110 million pre-IPO round to expand its global footprint and advance its lead candidate, a GPC3-targeted autologous CAR T therapy for liver cancer to registrational trials.
Regeneron Pharmaceuticals Inc. is entering the radiopharmaceutical space via a collaboration with Telix Pharmaceuticals Ltd. to jointly develop and commercialize next-generation radiopharmaceutical therapies.
Syneron Bio is emerging as one of the most heavily backed new entrants in the macrocyclic peptide space, raising more than $250 million in venture funding and securing a multibillion-dollar deal with Astrazeneca plc as it builds a platform spanning several of the most competitive frontiers in drug development.
Everest Medicines Ltd. has agreed to acquire a Singapore-based commercial unit of Hasten Biopharmaceuticals (Asia) Ltd. for $150 million up front, gaining market authorization holder rights to 14 marketed products originally developed by Takeda Pharmaceutical Co. Ltd.
More than four decades on from the approval of the first biologic drug, the industry has reached a tipping point, and biotech drugs now outnumber small molecules in the global R&D pipeline.
RSS
